U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 5Cl.Zn.3H4N
Molecular Weight 296.789
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMMONIUM PENTACHLOROZINCATE

SMILES

[NH4+].[NH4+].[NH4+].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Zn++]

InChI

InChIKey=IYBCULKOHOEVED-UHFFFAOYSA-L
InChI=1S/5ClH.3H3N.Zn/h5*1H;3*1H3;/q;;;;;;;;+2/p-2

HIDE SMILES / InChI

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Name Type Language
AMMONIUM PENTACHLOROZINCATE
MI  
Common Name English
AMMONIUM PENTACHLOROZINCATE [MI]
Common Name English
ZINCATE(3-), PENTACHLORO-, AMMONIUM (1:3)
Common Name English
AMMONIUM ZINC CHLORIDE ((NH4)3ZNCL5)
Common Name English
PENTACHLOROZINCATE(3-) AMMONIUM (1:3)
Common Name English
TRIAMMONIUM PENTACHLOROZINCATE
Common Name English
ZINCATE(3-), PENTACHLORO-, TRIAMMONIUM
Common Name English
Code System Code Type Description
PUBCHEM
11493111
Created by admin on Sat Dec 16 04:02:25 GMT 2023 , Edited by admin on Sat Dec 16 04:02:25 GMT 2023
PRIMARY
ECHA (EC/EINECS)
238-688-1
Created by admin on Sat Dec 16 04:02:25 GMT 2023 , Edited by admin on Sat Dec 16 04:02:25 GMT 2023
PRIMARY
MERCK INDEX
m1807
Created by admin on Sat Dec 16 04:02:25 GMT 2023 , Edited by admin on Sat Dec 16 04:02:25 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID20884763
Created by admin on Sat Dec 16 04:02:25 GMT 2023 , Edited by admin on Sat Dec 16 04:02:25 GMT 2023
PRIMARY
FDA UNII
3ILV18PW3Y
Created by admin on Sat Dec 16 04:02:25 GMT 2023 , Edited by admin on Sat Dec 16 04:02:25 GMT 2023
PRIMARY
CAS
14639-98-6
Created by admin on Sat Dec 16 04:02:25 GMT 2023 , Edited by admin on Sat Dec 16 04:02:25 GMT 2023
PRIMARY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966